Table 3 Cox proportional hazards regression models examining the prognostic value of clinical factors and signatures derived from single proteins and apoptosis modelling
From: System-based approaches as prognostic tools for glioblastoma
Predictors | HR | 95% CI | P |
|---|---|---|---|
Age (continuous, n = 46) | 1.02 | 1.00–1.05 | 0.06 |
Sex (ref. M, n = 24) |  |  | 0.40 |
 F (n = 22) | 0.76 | 0.41–1.43 |  |
Location (ref. left side, n = 13) |  |  | 0.58 |
 Right side (n = 28) | 1.28 | 0.62–2.64 |  |
 Other (n = 4) | 0.73 | 0.20–2.66 |  |
History (ref. newly-diagnosed - no treatment, n = 31) |  |  | 0.06 |
 Recurrent - no treatment (n = 6) | 1.86 | 0.69–5.01 |  |
 Recurrent - treatment (n = 9) | 2.73 | 1.19–6.25 |  |
MGMT promoter methylation (ref. methylated, n = 17) |  |  | 0.52 |
 Unmethylated (n = 22) | 1.26 | 0.62–2.59 |  |
Apaf-1 (ref. >median, n = 23) |  |  | 0.20 |
 ≤ median (n = 23) | 1.52 | 0.80–2.87 |  |
Procaspase-3 (ref. >median, n = 23) |  |  | 0.06 |
 ≤ median (n = 23) | 1.91 | 0.99–3.69 |  |
Procaspase-9 (ref. >median, n = 23) |  |  | 0.49 |
 ≤ median (n = 23) | 1.25 | 0.66–2.37 |  |
SMAC (ref. >median, n = 23) |  |  | 0.38 |
 ≤ median (n = 23) | 1.34 | 0.70–2.55 |  |
XIAP (ref. >median, n = 23) |  |  | 0.47 |
 ≤ median (n = 23) | 1.27 | 0.67–2.40 |  |
Apoptosis susceptibility (ref. SC > 80%, n = 37) |  |  | 0.001 |
 SC ≤ 80% (n = 9) | 5.02 | 2.04–12.33 |  |
Adjusted apoptosis susceptibility (ref. SC > 80%, n = 37)a |  |  | 0.006 |
 SC ≤ 80% (n = 9) | 4.40 | 1.59–12.14 |  |